Scarica l'app Stockscreener
3.92
1.01%
-0.04
Precedente Chiudi:
$3.96
Aprire:
$4
Volume 24 ore:
14,548
Relative Volume:
0.52
Capitalizzazione di mercato:
$88.86M
Reddito:
$35.16M
Utile/perdita netta:
$-11.44M
Rapporto P/E:
-6.5761
EPS:
-0.5961
Flusso di cassa netto:
$-15.44M
1 W Prestazione:
+2.08%
1M Prestazione:
-9.89%
6M Prestazione:
-37.88%
1 anno Prestazione:
-39.60%
Intervallo 1D:
$3.91
$4.048
Intervallo di 1 settimana:
$3.76
$4.26
Portata 52W:
$3.57
$12.80
Bioharvest Sciences Inc Stock (BHST) Company Profile
Nome
Bioharvest Sciences Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare BHST vs KHC, GIS, JBS, MKC, HRL
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHST
Bioharvest Sciences Inc
|
3.92 | 89.76M | 35.16M | -11.44M | -15.44M | -0.5961 |
KHC
Kraft Heinz Co
|
23.28 | 27.69B | 24.99B | -5.76B | 3.95B | -4.863 |
GIS
General Mills Inc
|
33.77 | 17.85B | 18.37B | 2.22B | 1.65B | 4.0676 |
JBS
Jbs Nv
|
12.49 | 13.77B | 66.64B | 1.80B | 773.23M | 1.7184 |
MKC
Mccormick Co Inc
|
47.25 | 12.55B | 7.11B | 1.65B | 680.40M | 6.1005 |
HRL
Hormel Foods Corp
|
20.40 | 11.21B | 12.14B | 489.00M | 577.53M | 0.8886 |
Bioharvest Sciences Inc Stock (BHST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | Roth Capital | Buy |
| 2025-05-05 | Iniziato | Craig Hallum | Buy |
| 2024-12-18 | Iniziato | Maxim Group | Buy |
Bioharvest Sciences Inc Borsa (BHST) Ultime notizie
Bioharvest Sciences Signals Progress Amid Near-Term Losses - TipRanks
BioHarvest Sciences and Tate & Lyle expand sweetener development program - Proactive financial news
BioHarvest (BHST) Q1 2026 Earnings Transcript - AOL.com
BioHarvest expands Tate & Lyle sweetener development deal By Investing.com - Investing.com Australia
Tate & Lyle expands plant-based sweetener innovation partnership with BioHarvest Sciences - New Food
BioHarvest expands Tate & Lyle sweetener development deal - Investing.com
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation - TMX Newsfile
New plant-based sweeteners aim to cut sugar in more foods - Stock Titan
BioHarvest Sciences Q1 earnings call highlights - MSN
BioHarvest outlines 2026 revenue of $38M-$42M in D2C and $12M-$14M in CDMO activity while targeting 2H 2027 fragrance production - MSN
H.C. Wainwright Maintains BioHarvest Sciences(BHST.US) With Buy Rating, Maintains Target Price $14 - Moomoo
BioHarvest Sciences Inc. Common Stock Q1 2026 Earnings Call Summary - Yahoo Finance
BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: - GuruFocus
BioHarvest Sciences (NASDAQ:BHST) Announces Quarterly Earnings Results - MarketBeat
BioHarvest Sciences Inc. (BHST) reports Q4 loss, lags revenue estimates - MSN
BioHarvest Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioHarvest Sciences Posts Q1 2026 Growth and Advances Botanical Synthesis Deals - TipRanks
BioHarvest Sciences: Q1 revenue up 8% YoY, CDMO revenue up 135%, net loss at $2.6M, gross margin at 59% - TradingView
BioHarvest Sciences (NASDAQ: BHST) posts Q1 2026 growth with $8.5M revenue - Stock Titan
Small cap wrap: VivoPower, BioHarvest Sciences, Phunware, Tiziana Life Sciences… - Proactive financial news
BioHarvest Sciences Files Q1 2026 Financials on Form 6-K - TipRanks
BioHarvest Sciences Q1 2026 Earnings Call Transcript - MarketBeat
BioHarvest Sciences (NASDAQ: BHST) grows Q1 2026 revenue while warning on going concern - Stock Titan
BioHarvest Sciences Names New Business Development Chief to Drive CDMO Growth - TipRanks
BioHarvest Sciences: Q1 revenue up 8% to $8.5M, CDMO and D2C segments advance, 2026 outlook reaffirmed - TradingView
New CDMO business development leader joins BioHarvest Sciences (NASDAQ: BHST) - Stock Titan
BioHarvest Sciences Q1 Earnings Call Highlights - MarketBeat
BioHarvest Sciences: Q1 2026 revenue up 8% to $8.5M; key CDMO and D2C milestones achieved; cash at $20.2M - TradingView
BioHarvest Sciences Inc. (BHST) reports Q1 loss, beats revenue estimates - MSN
BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline - Proactive financial news
BioHarvest Sciences : First Quarter 2026 Financial Statements - marketscreener.com
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
BioHarvest Sciences: Q1 revenue up 8% year-over-year, driven by CDMO and VINIA growth; net loss at $2.6 million - TradingView
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update - TradingView
BioHarvest Sciences produces active plant ingredients without growing the plant itself - Proactive financial news
BioHarvest appoints Salzman-Frenkel as VP business development - Investing.com UK
BioHarvest appoints Salzman-Frenkel as VP business development By Investing.com - Investing.com Nigeria
She closed $30M in drug contracts; now she’ll hunt CDMO deals for BioHarvest - Stock Titan
Small cap wrap: TNR Gold, Power Metallic Mines, BioHarvest Sciences, Midnight Sun Mining… - Proactive financial news
BioHarvest Advances Saffron CDMO Program to Stage 2 After Completing Cell Bank Milestone - TipRanks
BioHarvest Sciences (NASDAQ: BHST) completes Stage 1 in $1.125M saffron deal - Stock Titan
BioHarvest advances saffron cell bank project to stage 2 By Investing.com - Investing.com India
BioHarvest Sciences advances synthetic saffron program with SaffronTech partnership - Proactive financial news
BioHarvest advances saffron cell bank project to stage 2 - Investing.com UK
$1.125M saffron cell project aims at sustainable health and flavor - Stock Titan
BioHarvest secures $1.2M fragrance development contract By Investing.com - Investing.com Australia
BioHarvest Sciences Installs Co-Founder Zaki Rakib as CEO in Strategic Leadership Shift - The Globe and Mail
BioHarvest Sciences Secures $1.2M Stage 2 CDMO Deal for Rare Fragrance Development - TipRanks
BioHarvest Sciences Signs $1.2 Mln CDMO Stage 2 Contract - TradingView
BioHarvest Sciences (NASDAQ: BHST) lands $1.2M Stage 2 rare fragrance deal - Stock Titan
Bioharvest Sciences Inc Azioni (BHST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
1.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):